Related Experiment Video
Updated: Aug 18, 2025

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
Published on: August 9, 2022
[Application of genome editing technology in gene therapy]
Takafumi Hiramoto1, Tsukasa Ohmori1
1Department of Biochemistry, Jichi Medical University School of Medicine.
Abstract:
Genome editing has been attracting increasing attention as a new treatment for several refractory diseases since the CRISPR-Cas discovery has facilitated easy modification of target chromosomal DNA. The concept of treating refractory diseases by genome editing has been achieved in various animal models, and genome editing has been applied to human clinical trials for β-thalassemia, sickle cell disease, mucopolysaccharidosis, transthyretin amyloidosis, HIV infection, and CAR-T therapy. The genome editing technology targets the germline in industrial applications in animals and plants and is directed at the chromosomal DNA of the somatic cells in human therapeutic applications. Genome editing therapy for germline cells is currently forbidden due to ethical and safety concerns. Concerns regarding genome editing technology include safety (off-target effects) as well as technical aspects (low homologous recombination). Various technological innovations for genome editing are expected to expand its clinical application to various diseases in the future.
Related Concept Videos
Gene Therapy
What is Genetic Engineering?
CRISPR
Microorganisms in Medicine and Therapeutics
CRISPR/Cas9 Genome Editing
In-vitro Mutagenesis

